SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2002-01-0316. This Article Abstract Full Text (PDF) All Versions of this Article: 2002-01-0316v1 100/4/1340    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sethi, S. Articles by Mayadas, T. N. Search for Related Content PubMed PubMed Citation Articles by Sethi, S. Articles by Mayadas, T. N. Related Collections Hemostasis, Thrombosis, and Vascular Biology Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2002, Vol. 100, No. 4, pp. 1340-1346 HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR Sanjeev Sethi, Ouliana Ziouzenkova, Heyu Ni, Denisa D. Wagner, Jorge Plutzky, and Tanya N. Mayadas From the Vascular Research Division, Department of Pathology, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Center for Blood Research and Department of Pathology, Harvard Medical School, Boston, MA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Omega-3 fatty acids, which are abundant in fish oil, improve the prognosis of several chronic inflammatory diseases although the mechanism for such effects remains unclear. These fatty acids, such as eicosapentaenoic acid (EPA), are highly polyunsaturated and readily undergo oxidation. We show that oxidized, but not native unoxidized, EPA significantly inhibited human neutrophil and monocyte adhesion to endothelial cells in vitro by inhibiting endothelial adhesion receptor expression. In transcriptional coactivation assays, oxidized EPA potently activated the peroxisome proliferator-activated receptor  (PPAR), a member of the nuclear receptor family. In vivo, oxidized, but not native, EPA markedly reduced leukocyte rolling and adhesion to venular endothelium of lipopolysaccharide (LPS)-treated mice. This occurred via a PPAR-dependent mechanism because oxidized EPA had no such effect in LPS-treated PPAR-deficient mice. Therefore, the beneficial effects of omega-3 fatty acids may be explained by a PPAR-mediated anti-inflammatory effect of oxidized EPA. (Blood. 2002;100:1340-1346) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Consumption of omega-3 fatty acids in fish oil has been reported to improve the prognosis of several chronic inflammatory diseases characterized by leukocyte accumulation, including atherosclerosis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, and rheumatoid arthritis.1-4 Fish oil is also recommended for treatment of IgA nephropathy, the most common form of primary renal disease worldwide.5,6 Several studies suggest that omega-3 fatty acid supplementation may reduce the inflammatory response by attenuating leukocyte adhesion to the vessel wall.7-9 However, the primary mechanism for the anti-inflammatory effects of fish oil remains unclear.10 Omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are highly polyunsaturated and readily undergo oxidation.11 This suggests the possibility that oxidized omega-3 fatty acids may be an important component of the observed anti-inflammatory effects of fish oil. Indeed, Sethi and colleagues showed that oxidized EPA and DHA are more potent than native fatty acids in reducing RNA levels of leukocyte adhesion receptors and the adhesion of leukocyte cell lines to endothelial cells in vitro.12 Polyunsaturated fatty acids may exert their effects in cells by activation of peroxisome proliferator-activated receptors (PPARs). PPARs are ligand-activated transcription factors that regulate genes important in cell differentiation and various metabolic processes. Known PPAR isoforms include PPAR, important in lipoprotein metabolism, adipogenesis, and insulin sensitivity; PPAR, implicated in fatty acid metabolism; and PPAR, about which the least is known.13,14 Synthetic PPAR ligands such as fibrates (eg, fenofibric acid) are used in patients to lower triglyceride-rich lipoproteins. Synthetic PPAR ligands such as thiazolidinediones (eg, rosiglitazone) are insulin-sensitizing drugs used in the treatment of diabetes. Polyunsaturated fatty acids and eicosanoids are known natural ligands of PPAR, , and  although they are required in relatively high concentrations (approximately 100 µM) for PPAR activation and are not selective for PPAR subtypes.15,16 On the other hand, derivatives of fatty acids further activate PPAR and can exhibit selectivity for PPAR or PPAR in in vitro assays. For example, a cyclo-oxygenase product of arachidonic acid, 15d-delta12,14-PGJ2, is a selective PPAR ligand, whereas its lipoxygenase product 8(S)hydroxy-(5Z,9E, 11Z,14Z)-eicosatetraenoic acid (HETE) is a selective PPAR agonist.17 Recently, both PPAR and PPAR were identified in endothelial cells.14 Synthetic PPAR agonists decreased the transcription of endothelial vascular cell adhesion molecule 1 (VCAM-1) and the adhesion of HL60 cells to cytokine-activated endothelial cells.18 Other studies suggest that PPAR agonists may also inhibit cytokine-induced VCAM-1 expression,19,20 although such effects were not seen in vivo.21 The aim of this study was to determine the effects of oxidized versus native omega-3 fatty acid, EPA, on the interaction of human blood leukocytes with endothelial cells in vitro, to examine if PPARs are activated by oxidized EPA and are therefore potential targets of oxidized EPA-mediated effects, and to determine the relevance of the paradigm established in vitro, in lipopolysaccharide (LPS)-mediated inflammation in vivo. Our results show that oxidized EPA inhibits the adhesion of freshly isolated human peripheral blood neutrophils and monocytes to an activated endothelial cell monolayer under static and physiologic flow conditions, by reducing the surface expression of leukocyte adhesion receptors. We demonstrate that oxidized EPA potently activates PPAR to levels seen with fenofibric acid, a well-characterized synthetic PPAR agonist. Finally, we demonstrate that oxidized EPA, but not native EPA, significantly decreases leukocyte adhesion to the inflamed endothelium in vivo and that activation of PPAR is essential for this effect.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Preparation of fatty acids The EPA was purchased specifically from Cayman Chemicals (Ann Arbor, MI). It was relatively unoxidized as assessed by the thiobarbituric acid (TBA)-reactive substances (TBARs) assay using malondialdhyde (MDA) as a standard; this assay is a measure of fatty acid oxidation.22 EPA was dissolved in 100% ethanol and stored as a 100-mM stock under nitrogen to ensure minimal oxidation. Then, 3.3 mM EPA was made up in phosphate-buffered saline (PBS), and 5 µM cupric sulfate and 300 µM ascorbic acid were sequentially added and are referred to as oxidizing reagents. The sample was incubated at 37°C for 12 hours. Extensive oxidation was observed as assessed by TBARs. For treatment of cells, oxidized EPA or native EPA was diluted in media containing 20% fetal calf serum (FCS) to final concentrations between 10 and 100 µM. The vehicle control for oxidized EPA was media containing PBS plus oxidizing agents. Adhesion assay Human umbilical vein endothelial cell (HUVEC) monolayers in 96-well plates were pretreated for 1 hour with vehicle control, native EPA (100 µM), or oxidized EPA (10, 50, 100 µM) in standard growth medium. After 1 hour, the HUVECs were washed, the medium was replaced, and the cells were stimulated with LPS (50 ng/mL; Sigma Chemical, St Louis, MO), human interleukin 1 (IL-1; 10 U/mL), or human tumor necrosis factor  (TNF-; 10 ng/mL) for 5 hours. Leukocytes were fluorescently labeled with the fluorescent probe bis-carboxyethyl-carboxyfluorescein, acetoxymethyl ester (BCECF-AM; Molecular Probes, Eugene, OR), added to wells (6 × 104/well), and incubated for 10 minutes at 37°C. The wells were washed and filled with media; the plates were sealed, inverted, and spun at 100g for 5 minutes to remove nonadherent leukocytes. Adherence of labeled leukocytes was determined in a plate reader. Control studies indicated that fluorescence was a linear function of leukocytes in the range of 3000 to 60 000 cells/microplate well. Based on the standard curve obtained, the results are reported as the number of neutrophils or monocytes adherent per well of endothelial cells. Parallel plate flow assay Confluent HUVECs plated on a coverslip were treated as described for the adhesion assay. The HUVECs were placed in a parallel plate flow chamber under defined laminar flow, and neutrophils (106/mL) were applied at fluid shear stress varying from 2 to 0.25 dynes/cm2 as previously described.23 Leukocyte behavior was recorded on videotape and analyzed. The number of rolling and adherent neutrophils were determined in a minimum of 5 high power fields (× 20 magnification; 20 s/field) at each shear stress and averaged. Fluorescent immunoassay The HUVEC monolayers in 96-well plates were treated as indicated above. The cells were washed with RPMI with 1% FBS and placed on ice. Primary monoclonal antibodies to intercellular adhesion molecule 1 (ICAM-1), E-selectin, VCAM-1, endoglin, and HLA class I were diluted in RPMI-1% FBS and added to each well for 1 hour on ice. The cells were washed 3 times with RPMI-1% FBS and fluorescein isothiocyanate F(ab)2 goat antimouse IgG was added to each well. After incubation for 1 hour on ice the cells were washed twice with Dulbecco PBS containing 20% FBS (to quench nonspecific binding) and twice with DPBS. The cells were solubilized with lysis buffer and the fluorescence was read in a fluorescence microplate reader. Transcriptional coactivation assay Transient transfection was carried out in primary bovine aortic endothelial cells using the Superfect method (Qiagen, Valencia, CA) according to the manufacturer's protocols. Briefly, cells were plated in 24-well plates at 2.3 × 104 cells/well in Dulbecco modified Eagle medium (DMEM) containing 5% FCS. After 16 hours of growth, cells were washed with Hanks balanced salt solution (HBSS) and transfected with medium containing Superfect/DNA complexes (ratio 5.5:1) for 4 hours. Reporter construct pUASx4-TK-luc and chimeric human PPAR-ligand-binding domain (LBD) constructs have been described previously.24 PCMX--galactosidase expression vector was used as a transfection control. Transfected cells were left overnight in medium, followed by treatment with the indicated compounds for 10 hours. Luciferase activity was assayed in a lysis buffer (Pharmingen, San Diego, CA) using a reporter assay system (Pharmingen) according to the manufacturer's instructions. Activity of -galactosidase was monitored at 540 nm using chlorophenyl red -D galactopyranoside (Boehringer Mannheim, Indianapolis, IN) as a substrate. Rosiglitazone and fenofibric acid were used at concentrations of 1 µM and 100 µM, respectively. Intravital microscopy of mesenteric venules Four-week-old 129SV wild-type and PPAR/ mice25 (inbred 129SV strain, Jackson Laboratories, Bar Harbor, ME) were injected intraperitoneally with 500 µL PBS with oxidation reagents (vehicle), 500 µL 3.3 mM oxidized EPA (to achieve approximately 275 µM concentration in the blood assuming 3 mL blood volume and 3 mL extravascular fluid and equal distribution between these 2 compartments), or with 500 µL 3.3 mM native unoxidized EPA in PBS. One hour later the mice were given an intraperitoneal injection of LPS (1 µg in 100 µL PBS). Five hours later mice were anesthetized and the mesentery was gently exteriorized and prepared for intravital microscopy as previously described.26 Rolling leukocytes were quantitated in venules of 25 to 35 µm in diameter by counting the number of cells passing a given plane perpendicular to the vessel axis in 3 minutes, and the number per minute was calculated. Centerline erythrocyte velocity (Vrbc) was measured using an optical Doppler velocimeter and venular shear rate was calculated as previously described.26 A minimum of 3 venules was studied per animal. Leukocytes adherent to the vessel wall were counted per square millimeter of venular area at the end of every 3 minutes. At the end of the experimental procedure, peripheral blood was collected from the retro-orbital plexus and total leukocyte counts were determined.26 Experimental procedures were approved by the Harvard Medical Area Standing Committee on Animals. Statistical analysis Data are presented as average ± SEM. Statistical significance was assessed by the unpaired Student t test.     Results Top Abstract Introduction Materials and methods Results Discussion References Generation of oxidized EPA Unoxidized EPA was diluted in media and subjected to oxidation by the addition of cupric sulfate and ascorbic acid as described in "Materials and methods." Gas chromatography mass spectrometry of the samples revealed a single peak in the unoxidized EPA sample, which was consistent with native EPA, whereas oxidized EPA had less than 1% of the native EPA and a number of additional peaks that likely correspond to EPA oxidation products (data not shown). The extent of EPA oxidation in unoxidized or oxidized EPA is quantitated by measuring the amount of aldehydes present as previously reported.12 The aldehyde content of 100 µM unoxidized EPA was less than 0.02 µM MDA. Oxidized EPA was 1.78µM MDA in 100 µM EPA,12 which is in the range seen in plasma of humans (1.52-3.45 µM MDA) and animals (1.93 µM MDA) fed fish oil diets.27-31 Unoxidized EPA diluted in PBS to 100 µM and exposed to air (but not additional oxidizing agents) for 2 days at 37°C also showed significant oxidation (1.44 µM MDA), which highlights the propensity for this highly polyunsaturated fatty acid to oxidize. Oxidized EPA inhibits neutrophil and monocyte interaction with the endothelium under static adhesion and fluid shear stress conditions In static adhesion assays, pretreatment of HUVECs with oxidized EPA for 1 hour prior to LPS stimulation significantly inhibited the adhesion of peripheral blood human neutrophils and monocytes, whereas incubation with unoxidized, native EPA had little effect (Figure 1A,B). The inhibition of LPS-induced adhesion was dose dependent; 100 µM oxidized EPA reduced leukocyte adhesion to levels close to those seen for unstimulated HUVECs. Oxidized EPA similarly inhibited neutrophil adhesion to HUVECs activated with TNF- or IL-1 (Figure 1C). The effect of oxidized EPA on leukocyte rolling and firm adhesion to HUVECs under fluid shear stress conditions was assessed using a parallel plate flow chamber.23 HUVECs stimulated with LPS for 5 hours supported significant neutrophil rolling and adhesion under flow (0.5 dynes/cm2). Treatment of HUVECs with oxidized EPA for 1 hour prior to LPS stimulation significantly inhibited both rolling (Figure 2A) and adhesion (Figure 2B), whereas native EPA had no effect. View larger version (31K): [in this window] [in a new window]   Figure 1. Effect of oxidized EPA on neutrophil and monocyte adhesion to endothelial cells. HUVECs were pretreated for 1 hour with vehicle alone (Veh, PBS plus oxidizing reagents) or native (EPA) or oxidized EPA (oxEPA) at the indicated concentrations. HUVECs were then stimulated with LPS for 5 hours and assayed for human neutrophil (A) or monocyte (B) adhesion. (C) Endothelial cells were pretreated for 1 hour with vehicle alone (Veh), 100 µM native (EPA), or oxidized EPA (oxEPA). HUVECs were then incubated with TNF- (stippled bars) or IL-1 (solid bars) and assayed for neutrophil adhesion. Results are expressed as number of leukocytes attached per well of endothelial cells (± SEM). *P < .00001 compared with EPA + LPS or IL-1 or TNF, and Veh + LPS or IL-1 or TNF, n = 3. View larger version (30K): [in this window] [in a new window]   Figure 2. Effect of oxidized EPA on rolling and adhesion of neutrophils under laminar flow. HUVECs were treated with vehicle alone or native or oxidized EPA (100 µM) for 1 hour prior to stimulation with LPS for 5 hours. The HUVEC-containing coverslip was placed in a parallel plate flow chamber and resting neutrophils (106/mL) were infused at 0.5 dynes/cm2 wall shear stress. The number of rolling (A) and adherent neutrophils (B) were determined and averaged ± SEM. *P < .00007 compared with Veh + LPS, n = 3. Oxidized EPA inhibits cytokine-induced surface expression of leukocyte adhesion receptors on endothelial cells Stimulation of HUVECs with LPS induces expression of adhesion receptors, such as E-selectin, and VCAM-1 and ICAM-1, which support leukocyte tethering and adhesion, respectively. Treatment with oxidized EPA resulted in a dose-dependent reduction in LPS-stimulated surface expression of ICAM-1, VCAM-1, and E-selectin, whereas treatment with native EPA did not (Table 1). Oxidized EPA had no significant effect on the expression of endoglin, a membrane protein that binds transforming growth factor  (TGF-), and HLA class I molecules, which are constitutively expressed.                                View this table: [in this window] [in a new window]   Table 1. Effect of oxidized EPA on expression of endothelial adhesion molecules PPAR is activated in endothelial cells treated with oxidized EPA We tested the possibility that oxidized EPA exerts its effects on endothelial cells through PPARs, hypothesizing that oxidation of EPA might increase its ability to activate PPARs as compared with native EPA. Using 2 hybrid transcriptional coactivation assays in bovine aortic endothelial cells (BAECs),24 we found that both oxidized and native EPA can modestly activate PPAR in a dose-independent manner (Figure 3A). In contrast, oxidized EPA potently activates PPAR in a dose-dependent manner from 5 to 30 µM and was approximately 2- to 2.5-fold stronger than native EPA at equivalent concentrations. Interestingly, the activity by oxidized EPA was at least as potent as fenofibric acid, a well-documented synthetic PPAR ligand (Figure 3B). The estimated half-maximal activity for oxidized EPA was 10 µM as compared with an EC50 of 30 µM for fenofibric acid. View larger version (27K): [in this window] [in a new window]   Figure 3. Oxidized EPA activates PPAR-dependent transcription in BAECs. PPAR (A) or PPAR (B) activation was studied in BAECs using a yeast 2-hybrid Gal4 transfection assay for ligand-dependent activation. Cells were transfected with PPAR-LBD or PPAR-LBD fused to the yeast transcription factor Gal4, or a control Gal4 plasmid. All cells were transfected with a yeast Gal4-binding site luciferase reporter construct. Activation events at the LBD were measured by increased luciferase activity. Gal4 alone is not activated in mammalian cells. Cells were treated with native EPA (EPA), oxidized EPA (oxEPA), or synthetic agonists of PPAR (fen acid: fenofibric acid, 100 µM) or PPAR (roz: rosiglitazone, 1 µM). (A) Oxidized EPA led to a modest induction of PPAR activation that was not dose dependent and was comparable to that observed with native EPA. (B) Dose-response curves for PPAR activation by native EPA (closed square) or oxidized EPA (closed diamond) are shown. Native and oxidized EPA treatment of cells transfected with the control Gal4 construct (open symbols) revealed no luciferase activity. Insert shows PPAR activation by fenofibric acid (fen acid; 100 µM), but not by vehicle (Veh) alone. Analysis of the effects of 100-µM doses of oxidized EPA on PPAR and PPAR activation was not possible because unlike HUVECs, which were viable and responsive to cytokines at this dose of EPA, this concentration was toxic to the transfected BAECs likely because the transfection protocol or the expression of high levels of the LBD construct is somewhat toxic to the cells. Untransfected BAECs treated with 100 µM EPA remained viable. Thus, oxidized EPA potently activates PPAR in endothelial cells, which may explain the observed reduction in LPS-induced endothelial cell-receptor expression and leukocyte adhesion. Oxidized EPA reduces leukocyte-endothelial interactions in vivo through activation of PPAR Next, we determined if oxidized versus native EPA reduced leukocyte adhesion during inflammation in vivo and, if so, whether this occurred through a PPAR-dependent mechanism. Wild-type mice and mice deficient in PPAR were given an intraperitoneal injection of oxidized EPA, native EPA, or vehicle alone. After 1 hour, mice were injected intraperitoneally with LPS and 5 hours later underwent surgery and intravital microscopy of their mesenteric venules. In wild-type mice, LPS induced significant rolling and firm adhesion of leukocytes to the endothelium (Figure 4). Similar levels of rolling and adhesion were observed in LPS-treated PPAR-deficient mice suggesting that PPAR does not play a role in LPS-induced leukocyte adhesion to the endothelium. LPS-injected wild-type mice pretreated with oxidized EPA, but not native EPA, had markedly reduced leukocyte rolling (75%) and adhesion (75%) to inflamed venular endothelium compared with LPS-injected wild-type mice pretreated with vehicle alone. Indeed, levels of rolling and adhesion in the LPS- and oxidized EPA-treated mice approached those seen in mice injected with vehicle alone (Figure 4). In contrast, LPS-treated PPAR-deficient mice pretreated with native or oxidized EPA demonstrated no decrease in leukocyte rolling and adhesion compared to wild-type or PPAR-deficient mice treated with LPS alone. Peripheral blood leukocyte counts and venular shear rates were comparable among all the different groups of mice (data not shown). Together, these data indicate that oxidized EPA inhibits leukocyte-endothelial interactions in vivo and that this occurs through a PPAR-dependent mechanism. The much stronger inhibitory effect of oxidized EPA versus native EPA on leukocyte adhesion in wild-type animals correlated well with its more potent activation of PPAR in endothelial cell cultures compared to native EPA (Figure 3B), a difference not seen for PPAR activation (Figure 3A). View larger version (53K): [in this window] [in a new window]   Figure 4. Effect of oxidized EPA on leukocyte rolling and adhesion in mesenteric venules in wild-type and PPAR-deficient mice. Wild-type or PPAR-deficient mice (PPAR/) were given an intraperitoneal injection of vehicle (Veh) alone, native EPA, or oxidized EPA (oxEPA) 1 hour prior to injection of LPS. Five hours later mice were anesthetized and mesenteric venules were observed. Rolling (A) and adherent leukocytes (B) were determined; n = 5 to 7 for each group of mice. *P < .03 compared with Veh + LPS (wild type) and oxidized EPA + LPS (PPAR/). (C) Representative photographs of leukocytes interacting with the vessel wall (arrows) in LPS-stimulated wild-type and PPAR/ mice, after indicated treatments, are shown. Pictures were taken with a × 32 objective.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Our data suggest that the beneficial effects of fish oil in chronic inflammatory diseases may be due to the oxidative modification of omega-3 fatty acids and its subsequent inhibition of leukocyte adhesion receptor expression and leukocyte-endothelial interactions. Oxidized EPA significantly inhibited LPS-induced leukocyte rolling and adhesion, which are processes mediated by leukocyte adhesion receptors of the selectin, integrin, and IgG superfamily, respectively.32 Native EPA had no effect on leukocyte recruitment in these models. Our proposed mechanism of omega-3 fatty acid actions may also contribute to the decreased atherosclerosis among populations with high intake of fish rich in omega-3 fatty acids.4 The amount of oxidized EPA that yielded a decrease in leukocyte-endothelial interactions in vivo was approximately 275 µM in circulation, which may be achieved in humans with fish oil supplementation (700 µM total EPA)28 or diets rich in salmon.33,34 Oxidation of EPA leads to the generation of a mixture of aldehydes, peroxides, and other oxidation products, which are probably responsible for the observed anti-inflammatory effect.12 Although the structure(s) of the specific aldehyde/peroxide(s) responsible for the anti-inflammatory activity is not currently known, these products are undoubtedly present in humans consuming these fatty acids for the following reasons. Highly polyunsaturated long-chained EPA is readily oxidized at room temperature even in the absence of exogenous oxidizing reagents. More importantly, in vivo, a large increase in tissue and plasma accumulation of fatty acid oxidation products is noted in subjects consuming fish oil7,27,28,35 even after addition of antioxidant supplements to the diet,27,28 which suggests extensive oxidation of omega-3 fatty acids such as EPA in vivo. During inflammation, increased oxidation of dietary omega-3 fatty acids may occur due to increased oxidative stress, and the expression of enzymes (eg, cyclo-oxygenase and lipoxygenase) capable of oxidizing polyunsaturated fatty acids. On the other hand, fish oil consumption does not lead to an increase in oxidation of plasma proteins,28 which is important because protein oxidation can contribute to the development of diseases such as atherosclerosis.36,37 Endothelial cells have also been identified as a source of the omega-3 fatty acid DHA,38,39 which suggests the intriguing possibility that during inflammation, this fatty acid could be locally oxidized and serve as a potent natural anti-inflammatory mechanism for limiting the inflammatory response. Our study provides a mechanism by which oxidized EPA inhibits leukocyte-endothelial interactions. Both oxidized and native EPA modestly activated PPAR, but oxidized EPA potently activated PPAR in endothelial cells, and to a much greater extent than native EPA. Therefore, oxidation of the omega-3 fatty acid converts it into a stronger PPAR agonist. A recent study suggests that oxidized low-density lipoprotein (LDL) and not native LDL dose dependently activates PPAR in endothelial cells and that the oxidized phospholipid component is responsible for this effect.40 In particular, oxidized metabolites of linoleic acid, 9- and 13-hydroxyoctadecadienoic acid (9-HODE and 13-HODE) were potent PPAR ligands in endothelial cells.40 This, along with our study, suggests the possibility that oxidation of lipids may be one of the first steps involved in the generation of potent PPAR agonists in endothelial cells. Although our studies indicate that native EPA activates PPAR about half as well as oxidized EPA, it had no effect on leukocyte-endothelial interactions in vitro or in vivo. The reasons for this may include the following. The cotranscriptional Gal4 LBD assay is a valuable method of isolating one aspect of ligand-PPAR interaction, namely, the affinity of LBD for ligand. However, this assay excludes other cellular events that have an impact on PPAR-induced cellular transcriptional responses such as phosphorylation of PPAR41 or PPAR42 and the interaction between coactivators and corepressors with PPAR,43 all of which may differentially affect the ability of oxidized versus native EPA to modulate PPAR-mediated responses. For example, "nonproportional" responses have been seen for PPAR and the putative ligand 15dPGJ2. This prostaglandin demonstrates much less PPAR LBD affinity than the potent thiazolidinedione class of PPAR agonists24 but has comparable biologic effects to these drugs in vitro.24,44 Another explanation for the differential results of oxidized EPA and EPA in the in vivo and transfection assays is that PPAR activation by EPA seen in the cotranscriptional assays might remain beneath a threshold required for seeing a functional effect. These limitations of the cotransfection assay emphasize the importance of obtaining evidence for PPAR activation in in vivo settings. Indeed, we show that oxidized EPA significantly inhibited leukocyte-endothelial interactions in the complex environment of LPS-induced inflammation in mice in vivo, a response that was absent in PPAR-deficient mice. Together, our data demonstrate that oxidized EPA can both activate a PPAR LBD in vitro and exert potent antileukocyte adhesive effects in vivo, which are entirely PPAR dependent. On the other hand, LPS treatment of wild-type and PPAR-deficient mice led to significant leukocyte rolling and adhesion, which was comparable in both genotypes, suggesting that PPAR does not play a role in LPS-induced leukocyte-endothelial cell interactions. To our knowledge, ours is the first demonstration that a PPAR agonist (oxidized EPA) has potent inhibitory effects on neutrophil-endothelial interactions in vivo.18-20 Our studies also indicate that unlike the in vitro studies, which report that PPAR activation leads to the down-regulation of select leukocyte adhesion receptors (VCAM-1 but not ICAM-1 or E-selectin),18 in vivo, PPAR is responsible for down-regulating a spectrum of adhesion molecules required for leukocyte rolling and adhesion. The down-regulatory effects of oxidized EPA-mediated PPAR activation is likely through an inhibition of LPS or cytokine-induced activation of the transcription factor nuclear factor B (NFB), which stimulates the transcription of several cytokine-inducible adhesion receptors including E-selectin and VCAM-1 (Figure 5). Evidence for this comes from studies demonstrating that ligand-activated PPAR can inhibit NFB activity through as yet partially unknown mechanisms (ie, direct interactions with the p65 subunit of NFB or increased synthesis of the NFB inhibitor, IB, have been implicated45-47), and previous data showing that oxidized EPA inhibits NFB activation.12 View larger version (39K): [in this window] [in a new window]   Figure 5. Model of the mechanism of oxidized EPA-mediated down-regulation of LPS-induced endothelial-leukocyte interactions. LPS interacts with the toll-like receptor (TLR) on endothelial cells, which ultimately leads to the phosphorylation of the NFB inhibitor IB, which is subsequently rapidly polyubiquinated and degraded by the proteosome. Released NFB subunits (p65/p50) translocate from the cytoplasm to the nucleus where they bind to NFB response elements on target genes such as E-selectin and VCAM-1 and drive their transcription. Oxidized EPA is taken up by endothelial cells and activates PPAR. PPAR inhibits NFB activation through partially understood mechanisms and thus abrogates target gene expression. Subsequent down-regulation of LPS-inducible leukocyte adhesion molecule expression at the cell surface leads to a reduction in leukocyte-endothelial interactions. The oxidized EPA-mediated activation of PPAR may be relevant in biologic responses beyond those that were studied here. It may accelerate fatty acid metabolism, which has implications for obesity, a known risk factor for cardiovascular disease and diabetes. In addition both fish oil and the PPAR agonist, fenofibrate, have cholesterol- and triglyceride-lowering effects, suggesting that oxidized EPA-induced PPAR activation may contribute to the lipid-lowering effect of fish oil, although a recent study in PPAR-deficient mice suggested PPAR and fish oil affect lipoprotein metabolism through different mechanisms.48 In summary, oxidized EPA is a potent inhibitor of leukocyte interactions with the endothelium compared to native EPA, both in vitro and in an in vivo context of inflammation. The effects of oxidized EPA are mediated through activation of PPAR, which is responsible for the down-regulation of leukocyte adhesion receptor expression required for leukocyte-endothelial interactions. We propose that oxidation of EPA and its activation of PPAR is one of the underlying mechanism for the beneficial effects of fish oil. Finally, given the potency of oxidized EPA in activating PPAR, and that its effects were comparable to those seen with the PPAR agonist, fenofibrate, our studies also suggest that oxidized omega-3 fatty acids may represent a class of naturally occurring, low-toxicity, PPAR agonists with potent anti-inflammatory properties.     Acknowledgments The authors would like to thank Ms Kay Case for providing HUVECs, and Drs F. W. Luscinskas and Y. C. Lym (Brigham and Women's Hospital, Boston, MA) for their help with the parallel plate flow chamber.     Footnotes Submitted February 1, 2002; accepted April 8, 2002. Prepublished online as Blood First Edition Paper, May 17, 2002; DOI 10.1182/blood-2002-01-0316. Supported by National Heart, Lung and Blood Institute HL36028 (T.N.M.), HL53756 (D.D.W.), a research award from the American Diabetes Association (J.P.), the LeDucq Center for Cardiovascular Research (J.P.), and the American Heart Association (S.S). H.N. is a research fellow of the Heart and Stroke Foundation of Canada. O.Z. and H.N. contributed equally to this work. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Tanya N. Mayadas, Department of Pathology, Brigham and Women's Hospital, 221 Longwood Ave, Room 404, Boston, MA 02130; e-mail: tmayadas{at}rics.bwh.harvard.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Belluzi A, Brignola C, Campieri M, Pera A, Boschi S, Migliolo M. Effect of an enteric coated fish oil preparation on relapses in Crohn's disease. N Engl J Med. 1996;334:1557-1560[Abstract/Free Full Text]. 2. Volker D, Fitzgerald P, Major G, Garg M. Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol. 2000;27:2343-2346[Medline] [Order article via Infotrieve]. 3. Bang JO, Dyberg J. Fish oil consumption and mortality from coronary heart disease. N Engl J Med. 1985;313:822-823. 4. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205-1209[Abstract]. 5. Donadio JV Jr, Bergstralh EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Eng J Med. 1994;331:1194-1199[Abstract/Free Full Text]. 6. Donadio JV Jr. Use of fish oil to treat patients with immunoglobulin A nephropathy. Am J Clin Nutr. 2000;71:273S-275S. 7. Kim DN, Schmee J, Thomas WA. Dietary fish oil added to a hyperlipidemic diet for swine results in reduction in the excessive number of monocytes attached to arterial endothelium. Atherosclerosis. 1990;81:209-216[CrossRef][Medline] [Order article via Infotrieve]. 8. Lehr HA, Hubner C, Finckh B, et al. Dietary fish oil reduces leukocyte/endothelium interaction following systemic administration of oxidatively modified low density lipoprotein. Circulation. 1991;84:1725-1731[Abstract/Free Full Text]. 9. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71:213S-223S[Abstract/Free Full Text]. 10. Grande JP, Donadio JV Jr. Dietary fish oil supplementation in IgA nephropathy: a therapy in search of a mechanism? Nutrition. 1998;14:240-242[CrossRef][Medline] [Order article via Infotrieve]. 11. Chan HWS. The mechanism of autoxidation. In: Autoxidation of Unsaturated Lipids. London, United Kingdom; Academic Press; 1987:1-16. 12. Sethi S, Eastman AY, Eaton JW. Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism? J Lab Clin Med. 1996;128:27-38[CrossRef][Medline] [Order article via Infotrieve]. 13. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000;2:327-335[Medline] [Order article via Infotrieve]. 14. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol. 2000;129:823-834[CrossRef][Medline] [Order article via Infotrieve]. 15. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997;94:4318-4323[Abstract/Free Full Text]. 16. Krey G, Braissant O, L'Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997;11:779-791[Abstract/Free Full Text]. 17. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497-505[CrossRef][Medline] [Order article via Infotrieve]. 18. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR activators inhibit cytokine induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131[Abstract/Free Full Text]. 19. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238[Abstract/Free Full Text]. 20. Jackson SM, Parhami F, Xi XP, Berliner JA, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094-2104[Abstract/Free Full Text]. 21. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531[Medline] [Order article via Infotrieve]. 22. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. 3rd ed. New York, NY: Oxford University Press; 1999. 23. Luscinskas FW, Kansas GS, Ding H, et al. Monocyte rolling, arrest and spreading on IL-4-activated vascular endothelium under flow is mediated via sequential action of L-selectin, 1-integrins, and 2 integrins. J Cell Biol. 1994;125:1417-1427[Abstract/Free Full Text]. 24. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803-812[CrossRef][Medline] [Order article via Infotrieve]. 25. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012-3022[Abstract]. 26. Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD. Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectin. Cell. 1996;84:563-574[CrossRef][Medline] [Order article via Infotrieve]. 27. Gonzalez MJ, Gray JI, Schemmel RA, Dugan L, Welsch CW. Lipid peroxidation products are elevated in fish oil diets even in the presence of added antioxidants. J Nutr. 1992;122:2190-2195[Abstract/Free Full Text]. 28. Wander RC, Du S-H. Oxidation of plasma proteins is not increased after supplementation with eicosapentaenoic and docosahexaenoic acids. Am J Clin Nutr. 2000;72:731-737[Abstract/Free Full Text]. 29. Pironi L, Ruggeri E, Zolezzi C, et al. Lipid peroxidation and antioxidant status in adults receiving lipid-based home parenteral nutrition. Am J Clin Nutr. 1998;68:888-893[Abstract]. 30. Johansen O, Seljeflot I, Hostmark AT, Arnesen H. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary disease. Arterioscler Thromb Vasc Biol. 1999;19:1681-1686[Abstract/Free Full Text]. 31. Kim DN, Schmee J, Lee CS, Eastman A, Ross JS, Thomas WA. Comparison of effects of fish oil and corn oil supplements on hyperlipidemic diet induced atherogenesis in swine. Atherosclerosis. 1991;89:191-201[CrossRef][Medline] [Order article via Infotrieve]. 32. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101[Abstract/Free Full Text]. 33. Wander RC, Patton BD. Comparison of three species of fish consumed as part of a Western diet: effects on platelet fatty acids and function, hemostasis, and production of thromboxane. Am J Clin Nutr. 1991;54:326-333[Abstract/Free Full Text]. 34. Gerhard GT, Patton BD, Lindquist SA, Wander RC. Comparison of three species of dietary fish: effects on serum concentrations of low-density-lipoprotein cholesterol and apolipoprotein in normotriglyceridemic subjects. Am J. Clin Nutr. 1991;55:141-142. 35. Meydani M. Omega-3 fatty acids alter soluble markers of endothelial function in coronary heart disease patients. Nutr Rev. 2000;58:56-59[Medline] [Order article via Infotrieve]. 36. Kwiterovich PO Jr. The effect of dietary fat, antioxidants, and pro-oxidants on blood lipids, lipoproteins, and atherosclerosis. J Am Diet Assoc. 1997;97:S31-S41[CrossRef][Medline] [Order article via Infotrieve]. 37. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516[CrossRef][Medline] [Order article via Infotrieve]. 38. Salem N, Kim HY, Yergey JA. Docosahexaenoic acid: membrane function and metabolism. In: Simopoulos AP,Kifer RR,Martin R, eds. The Health Effects of Polyunsaturated Fatty Acids in Seafoods. New York, NY: Academic Press; 1986:263-317. 39. Delton-Vandenbroucke I, Grammas P, Anderson RE. Polyunsaturated fatty acid metabolism in retinal and cerebral microvascular endothelial cells. J Lipid Res. 1997;38:147-159[Abstract]. 40. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett. 2000;471:34-38[CrossRef][Medline] [Order article via Infotrieve]. 41. Barger PM, Browning AC, Garner AN, Kelly DP. p38 MAP kinase activates PPAR{alpha}: a potential role in the cardiac metabolic stress response. J Biol Chem. 2001;276:44495-44501[Abstract/Free Full Text]. 42. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science. 1996;274:2100-2103[Abstract/Free Full Text]. 43. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121-141[Free Full Text]. 44. Brun RP, Tontonoz P, Forman BM, et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984[Abstract/Free Full Text]. 45. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-32054[Abstract/Free Full Text]. 46. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem. 2000;275:36703-36707[Abstract/Free Full Text]. 47. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-793[CrossRef][Medline] [Order article via Infotrieve]. 48. Dallongeville J, Bauge E, Tailleux A, et al. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem. 2001;276:4634-4639[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H.-H. Chen, T.-W. Chen, and H. Lin Prostacyclin-induced peroxisome proliferator-activated receptor-{alpha} translocation attenuates NF-{kappa}B and TNF-{alpha} activation after renal ischemia-reperfusion injury Am J Physiol Renal Physiol, October 1, 2009; 297(4): F1109 - F1118. [Abstract] [Full Text] [PDF] M. K. Duda, K. M. O'Shea, and W. C. Stanley {omega}-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential Cardiovasc Res, October 1, 2009; 84(1): 33 - 41. [Abstract] [Full Text] [PDF] H. Yamada, M. Yoshida, Y. Nakano, T. Suganami, N. Satoh, T. Mita, K. Azuma, M. Itoh, Y. Yamamoto, Y. Kamei, et al. In Vivo and In Vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid Arterioscler Thromb Vasc Biol, December 1, 2008; 28(12): 2173 - 2179. [Abstract] [Full Text] [PDF] J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF] G. Orasanu, O. Ziouzenkova, P. R. Devchand, V. Nehra, O. Hamdy, E. S. Horton, and J. Plutzky The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice J. Am. Coll. Cardiol., September 2, 2008; 52(10): 869 - 881. [Abstract] [Full Text] [PDF] J. McGuinness, J. Byrne, C. Condron, J. McCarthy, D. Bouchier-Hayes, and J. M. Redmond Pretreatment with {omega}-3 fatty acid infusion to prevent leukocyte-endothelial injury responses seen in cardiac surgery J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 135 - 141. [Abstract] [Full Text] [PDF] J. D. Brooks, G. L. Milne, H. Yin, S. C. Sanchez, N. A. Porter, and J. D. Morrow Formation of Highly Reactive Cyclopentenone Isoprostane Compounds (A3/J3-Isoprostanes) in Vivo from Eicosapentaenoic Acid J. Biol. Chem., May 2, 2008; 283(18): 12043 - 12055. [Abstract] [Full Text] [PDF] H. Yin, J. D. Brooks, L. Gao, N. A. Porter, and J. D. Morrow Identification of Novel Autoxidation Products of the {omega}-3 Fatty Acid Eicosapentaenoic Acid in Vitro and in Vivo J. Biol. Chem., October 12, 2007; 282(41): 29890 - 29901. [Abstract] [Full Text] [PDF] J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF] A. Ferrante, B. S. Robinson, H. Singh, H. P.A. Jersmann, J. V. Ferrante, Z. H. Huang, N. A. Trout, M. J. Pitt, D. A. Rathjen, C. J. Easton, et al. A Novel {beta}-Oxa Polyunsaturated Fatty Acid Downregulates the Activation of the I{kappa}B Kinase/Nuclear Factor {kappa}B Pathway, Inhibits Expression of Endothelial Cell Adhesion Molecules, and Depresses Inflammation Circ. Res., July 7, 2006; 99(1): 34 - 41. [Abstract] [Full Text] [PDF] W. C. Stanley, F. A. Recchia, and I. C. Okere Metabolic therapies for heart disease: Fish for prevention and treatment of cardiac failure? Cardiovasc Res, November 1, 2005; 68(2): 175 - 177. [Full Text] [PDF] P. R. Devchand, O. Ziouzenkova, and J. Plutzky Oxidative Stress and Peroxisome Proliferator-Activated Receptors: Reversing the Curse? Circ. Res., December 10, 2004; 95(12): 1137 - 1139. [Full Text] [PDF] A. Mishra, A. Chaudhary, and S. Sethi Oxidized Omega-3 Fatty Acids Inhibit NF-{kappa}B Activation Via a PPAR{alpha}-Dependent Pathway Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1621 - 1627. [Abstract] [Full Text] [PDF] Q. Jia, Y. Shi, M. B. Bennink, and J. J. Pestka Docosahexaenoic Acid and Eicosapentaenoic Acid, but Not {alpha}-Linolenic Acid, Suppress Deoxynivalenol-Induced Experimental IgA Nephropathy in Mice J. Nutr., June 1, 2004; 134(6): 1353 - 1361. [Abstract] [Full Text] [PDF] B. Nohe, T. Johannes, H.-J. Dieterich, K. Mayer, M. Merfels, F. Grimminger, and W. Seeger Antiinflammatory effects of {omega}-3 fatty acids vary at different stages of inflammation Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2248 - H2250. [Full Text] [PDF] O. Ziouzenkova, S. Perrey, L. Asatryan, J. Hwang, K. L. MacNaul, D. E. Moller, D. J. Rader, A. Sevanian, R. Zechner, G. Hoefler, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase PNAS, March 4, 2003; 100(5): 2730 - 2735. [Abstract] [Full Text] [PDF] K. Vanschoonbeek, M. P. M. de Maat, and J. W. M. Heemskerk Fish Oil Consumption and Reduction of Arterial Disease J. Nutr., March 1, 2003; 133(3): 657 - 660. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2002-01-0316v1 100/4/1340    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sethi, S. Articles by Mayadas, T. N. Search for Related Content PubMed PubMed Citation Articles by Sethi, S. Articles by Mayadas, T. N. Related Collections Hemostasis, Thrombosis, and Vascular Biology Signal Transduction Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020